Abstract
Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5- HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5- HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.
Keywords: Serotonin, antidepressant, depression, SSRI, synaptic neurotransmission of serotonin, selective serotonin reuptake inhibitors.
Current Pharmaceutical Design
Title:Recent Developments on Future Antidepressant-related Serotonin Receptors
Volume: 24 Issue: 22
Author(s): Meysam Amidfar and Yong-Ku Kim*
Affiliation:
- Department of Psychiatry, College of Medicine, Korea University, Seoul,South Korea
Keywords: Serotonin, antidepressant, depression, SSRI, synaptic neurotransmission of serotonin, selective serotonin reuptake inhibitors.
Abstract: Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5- HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5- HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.
Export Options
About this article
Cite this article as:
Amidfar Meysam and Kim Yong-Ku *, Recent Developments on Future Antidepressant-related Serotonin Receptors, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180803111240
DOI https://dx.doi.org/10.2174/1381612824666180803111240 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis of Renal Diseases Based on Machine Learning Methods Using Ultrasound Images
Current Medical Imaging On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Subset Selection and Docking of Human P2X7 Inhibitors
Current Computer-Aided Drug Design Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Withanolides from Withania somnifera Dunal: Development of Cellular Technology and their Production
Recent Patents on Biotechnology Review of Somnambulism in Children
Current Pediatric Reviews Betaxolol Hydrochloride Loaded Chitosan Nanoparticles for Ocular Delivery and their Anti-glaucoma Efficacy
Current Drug Delivery Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Current Pharmaceutical Design HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Current Diabetes Reviews Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Current Alzheimer Research The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Diabetes Mellitus Type 2 and Functional Foods of Plant Origin
Recent Patents on Biotechnology Differential Imbalances of Brain Glutamate/GABA in Patients with Bipolar Disorder and Unipolar Depression
Neuroscience and Biomedical Engineering (Discontinued) The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry Paroxetine Hydrochloride Push-pull Osmotic Pump Tablets: Designing an Innovative, Scalable Push-pull Osmotic Drug Delivery System Using QbD Approach
Drug Delivery Letters